| Jul 31,
2018 | Jul 31,
2019 | Jul 31,
2020 | Jul 31,
2021 | Jul 31,
2022 | Jul 31,
2023 | Jul 31,
2024 |
|---|
| Consolidated net loss | -12 | -5 | -11 | - | -142 | -2 | -65 |
|---|
| Less: Income from discontinued operations | - | - | - | - | 2 | - | - |
|---|
| Consolidated net loss from continuing operations | - | - | - | - | -141 | -9 | -65 |
|---|
| Depreciation and amortization | 2 | 2 | 2 | 1 | 0 | 0 | 0 |
|---|
| Gain on sale of property and equipment | - | - | - | - | - | - | 0 |
|---|
| Unrealized gain on investment - Hedge Funds | - | - | - | - | - | - | 0 |
|---|
| Unrealized gain on investment in equity securities | - | - | - | - | - | 0 | - |
|---|
| Realized loss on investment in equity securities | 0 | 0 | - | - | - | - | -0 |
|---|
| Realized gain on available-for-sale securities | - | - | - | - | - | 0 | 2 |
|---|
| Amortization of discount on available-for-sale securities | - | 0 | 0 | 0 | 0 | - | -2 |
|---|
| Loss on initial investment in Day Three upon acquisition | - | - | - | - | - | - | 2 |
|---|
| Realized gain in equity investments - Cyclo | - | - | - | - | - | - | 0 |
|---|
| Unrealized gain in equity investments - Cyclo | - | - | - | - | - | - | -0 |
|---|
| Unrealized gain on convertible notes receivable, due from Cyclo | - | - | - | - | - | - | 1 |
|---|
| Recovery of receivables from Cornerstone | - | - | - | - | - | - | -31 |
|---|
| In-process research and development expense | - | - | - | - | - | - | 90 |
|---|
| Gain on dissolution of a business | - | - | - | - | - | - | 0 |
|---|
| Equity in loss of Day Three | - | - | - | - | - | - | 0 |
|---|
| Bad debt expense | - | - | - | - | - | - | 0 |
|---|
| Stock-based compensation | - | - | - | 7 | -1 | 2 | 2 |
|---|
| Trade accounts receivable | - | - | - | - | -0 | 0 | 0 |
|---|
| Interest receivable | - | - | - | - | 0 | 0 | 0 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | -0 | 1 | 4 | -0 | -1 |
|---|
| Other assets | 1 | -0 | 0 | -0 | -0 | 0 | -0 |
|---|
| Accounts payable and accrued expenses | -0 | 1 | 1 | 0 | 0 | -1 | -0 |
|---|
| Other current liabilities | -0 | 0 | 0 | 0 | 4 | 1 | -1 |
|---|
| Due to related parties | - | - | -0 | - | - | -0 | 0 |
|---|
| Other liabilities | - | - | - | - | - | 0 | -0 |
|---|
| Net cash used in continuing operations | - | - | - | - | -26 | -10 | -8 |
|---|
| Net cash used in discontinued operations | - | - | - | - | -0 | -1 | - |
|---|
| Net cash used in operating activities | -2 | -3 | -5 | -16 | -26 | -11 | -8 |
|---|
| Purchase of property and equipment | 1 | 0 | 1 | 0 | - | - | 0 |
|---|
| Purchases of available-for-sale securities | - | - | - | - | - | - | 156 |
|---|
| Proceeds from the sale and maturities of available-for-sale securities | - | - | - | - | - | 185 | 153 |
|---|
| Proceeds from Day Three patent sale | - | - | - | 4 | - | - | 0 |
|---|
| Purchase of intangible assets | - | - | - | - | - | - | 0 |
|---|
| Proceeds from sales of equity securities | - | - | - | - | - | - | 0 |
|---|
| Issuance of Convertible Notes, Due from Cyclo | - | - | - | - | - | - | -4 |
|---|
| Purchase of Investment in Day Three | - | 56 | - | - | - | - | - |
|---|
| Purchase of Investment in Cyclo | - | - | - | - | - | - | 7 |
|---|
| Issuance of convertible note receivable | - | - | - | - | - | - | 1 |
|---|
| Issuance of Day Three Promissory Notes | - | - | - | - | - | 2 | 2 |
|---|
| Proceeds from investments - Other Pharmaceuticals | - | - | - | - | - | - | 0 |
|---|
| Purchases of equity securities | - | - | - | - | - | 2 | - |
|---|
| Cash acquired in acquisition of Day Three, net of cash payments | - | - | - | - | - | - | -1 |
|---|
| Cash acquired in the Cornerstone Acquisition, net of cash payments | - | - | - | - | - | - | -1 |
|---|
| Proceeds from hedge funds | - | - | - | - | - | - | 3 |
|---|
| Net cash used in investing activities of continuing operations | - | - | - | - | -64 | -27 | -11 |
|---|
| Payment of transaction costs for sale of 520 Property - discontinued operations | - | - | - | - | 2 | - | - |
|---|
| Net cash provided by investing activities of discontinued operations | - | - | - | - | -0 | 48 | - |
|---|
| Net cash (used in) provided by investing activities | 4 | -31 | -1 | -8 | -64 | 21 | -11 |
|---|
| Principal payments on installment note payable | - | - | - | - | - | - | 1 |
|---|
| Payments for taxes related to shares withheld for employee taxes | - | - | -0 | - | - | 0 | 0 |
|---|
| Purchases of treasury stock | - | - | - | - | - | - | 0 |
|---|
| Proceeds from sale of Rafael Medical Devices membership units | - | - | - | - | - | - | 1 |
|---|
| Net cash used in financing activities of continuing operations | - | - | - | - | 104 | -0 | -0 |
|---|
| Net cash used in financing activities of discontinued operations | - | - | - | - | - | -15 | - |
|---|
| Net cash used in financing activities | 2 | 31 | -0 | 30 | 104 | -15 | -0 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | -0 | -0 | -0 |
|---|
| Net decrease in cash and cash equivalents | - | - | - | - | 14 | -5 | -19 |
|---|
| Acquisition of additional ownership interest in LipoMedix | - | - | - | - | 0 | 0 | - |
|---|
| Conversion of RFL Line of Credit into Cornerstone Common Stock | - | - | - | - | - | - | 38 |
|---|
| Conversion of 2023 Promissory Note into Cornerstone Common Stock | - | - | - | - | - | - | 3 |
|---|
| Recognition of noncontrolling interest in the Cornerstone Acquisition | - | - | - | - | - | - | 28 |
|---|
| Recognition of noncontrolling interest in the RP Finance Consolidation, net of elimination | - | - | - | - | - | - | 10 |
|---|
| Gain on RP Finance Consolidation recorded as an adjustment to additional paid-in capital due to related party nature of transaction, net of elimination | - | - | - | - | - | - | 6 |
|---|
| Noncash consideration received in exchange for equipment | - | - | - | - | - | - | 0 |
|---|
| Elimination of principal and accrued interest on the Day Three Promissory Notes included in consideration for acquisition of Day Three | - | - | - | - | - | - | 2 |
|---|